Labcorp receives emergency use authorization for first non-prescription at-home collection kit for combined covid-19, flu and rsv detection

Burlington, n.c.--(business wire)--labcorp (nyse: lh), a leading global life sciences company, today announced the receipt of emergency use authorization (eua) from the u.s. food and drug administration (fda) for a combined at-home collection kit available that simultaneously detects covid-19, influenza a/b and respiratory syncytial virus (rsv), a common but contagious respiratory virus often seen in children. the pixel by labcorp covid-19+flu+rsv test home collection kit will be available for
LH Ratings Summary
LH Quant Ranking